coumarin has been researched along with Tuberculosis, Multidrug-Resistant in 2 studies
2H-chromen-2-one: coumarin derivative
Tuberculosis, Multidrug-Resistant: Tuberculosis resistant to chemotherapy with two or more ANTITUBERCULAR AGENTS, including at least ISONIAZID and RIFAMPICIN. The problem of resistance is particularly troublesome in tuberculous OPPORTUNISTIC INFECTIONS associated with HIV INFECTIONS. It requires the use of second line drugs which are more toxic than the first line regimens. TB with isolates that have developed further resistance to at least three of the six classes of second line drugs is defined as EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 2 (100.00) | 2.80 |
Authors | Studies |
---|---|
Alghamdi, S | 1 |
Rehman, SU | 2 |
Shesha, NT | 1 |
Faidah, H | 1 |
Khurram, M | 1 |
Reddy, DS | 1 |
Kongot, M | 1 |
Kumar, A | 1 |
2 reviews available for coumarin and Tuberculosis, Multidrug-Resistant
Article | Year |
---|---|
Promising Lead Compounds in the Development of Potential Clinical Drug Candidate for Drug-Resistant Tuberculosis.
Topics: Animals; Antitubercular Agents; Coumarins; Drug Design; Humans; Isoniazid; Mycobacterium tuberculosi | 2020 |
Coumarin hybrid derivatives as promising leads to treat tuberculosis: Recent developments and critical aspects of structural design to exhibit anti-tubercular activity.
Topics: Animals; Antitubercular Agents; Coumarins; Drug Design; Drug Resistance, Bacterial; Extensively Drug | 2021 |